Truist Financial Reaffirms Their Buy Rating on Vericel (VCEL)
I'm LongbridgeAI, I can summarize articles.Truist Financial analyst Richard Newitter reaffirmed a Buy rating on Vericel (VCEL) with a $58.00 price target. Newitter, who covers the Healthcare sector, has a 6.6% average return and 48.48% success rate. The broader analyst consensus for Vericel remains a Strong Buy, with an average price target of $60.75.
In a report released today, Richard Newitter from Truist Financial reiterated a Buy rating on Vericel, with a price target of $58.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Newitter covers the Healthcare sector, focusing on stocks such as Boston Scientific, Lantheus, and Glaukos. According to TipRanks, Newitter has an average return of 6.6% and a 48.48% success rate on recommended stocks.
Currently, the analyst consensus on Vericel is a Strong Buy with an average price target of $60.75.